A Phase 2 Study of XL147 (SAR245408) in Subjects With Advanced or Recurrent Endometrial Carcinoma

Trial Profile

A Phase 2 Study of XL147 (SAR245408) in Subjects With Advanced or Recurrent Endometrial Carcinoma

Discontinued
Phase of Trial: Phase II

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs Pilaralisib (Primary)
  • Indications Endometrial cancer
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 08 Jan 2013 Status changed from recruiting to discontinued, according to a Sanofi media release.
    • 20 Jun 2012 Planned End Date changed from 1 Mar 2013 to 1 Sep 2013 as reported by ClinicalTrials.gov.
    • 06 Jun 2012 Official Title amended as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top